Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common amino acid help fight colorectal cancer?

NCT ID NCT07577505

Disease control Sponsor: Jing-yuan Fang, MD, Ph. D Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 21, 2026 · Updated 3 times

Summary

This study tests whether taking histidine, an amino acid supplement, can safely boost the immune system's ability to fight colorectal cancer. Twenty participants will take 2 grams of histidine daily for 9 weeks alongside their standard cancer treatment. Researchers will measure changes in immune cell activity and tumor size.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Histidine (an amino acid supplement)
What this could lead to
If it works, this could point toward a simple dietary supplement to help the immune system fight colorectal cancer better alongside standard treatments.
What could go wrong
This is a very small, early-stage study with only 20 participants and no placebo group. It only measures immune markers, not whether the cancer actually shrinks or survival improves.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients aged 18-80 years, regardless of sex. 2. Body mass index (BMI) ≥18.5. 3. NRS-2002 score \<3. 4. Diagnosed with stage II or higher colorectal cancer who require pharmacological intervention. 5. Capable of oral intake of medication. 6. Willing to participate in the study and provide written informed consent. Exclusion Criteria: 1. Participation in other interventional clinical trials (including drugs, nutritional supplements, medical devices, etc.) within 4 weeks prior to enrollment. 2. Presence of ascites, severe diarrhea, intractable vomiting, severe malabsorption syndrome, paralysis, mechanical intestinal obstruction, or active gastrointestinal bleeding. 3. Allergy to sample components. 4. Current use of other nutritional supplements that may affect the validity and effectiveness of the study results. 5. Pregnant, lactating female patients or women with fertility who test positive in the baseline pregnancy test. 6. Presence of cognitive impairments or mental illnesses that prevent understanding of the study procedures. 7. Presence of any other conditions, judged by the researcher, make the participant unsuitable for participation in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colorectal cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Shanghai Punan Hospital of Pudong New District

    RECRUITING

    Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.